Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00946309 · ClinicalTrials.gov registry record · Phase 1

Effects of Sulforaphane on Normal Prostate Tissue

A Phase 1 study of Prostate Cancer, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT00946309 is a Phase 1 study of Prostate Cancer that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 45 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00946309, a Phase 1 study of Prostate Cancer, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The investigators proposed to identify the biological effects of a high-sulforaphane broccoli sprout extract in normal prostate tissue. The investigators hypothesize that consumption of high-sulforaphane broccoli sprout extract every other day will inhibit growth of prostate cancer cells.

Conditions Studied

Interventions

  • DRUG High Sulforaphane Extract (Broccoli Sprout Extract)
  • DRUG Microcrystalline Cellulose NF (placebo)

Study Locations (1)

Washington

  • VA Puget Sound - Seattle

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2010-07
Est. Completion 2015-05
Phase Phase 1

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT00946309

The ClinicalTrials.gov registry entry for NCT00946309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which High Sulforaphane Extract (Broccoli Sprout Extract) is the first listed.

NCT00946309 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00946309 about?

NCT00946309 is a clinical study titled "Effects of Sulforaphane on Normal Prostate Tissue". The investigators proposed to identify the biological effects of a high-sulforaphane broccoli sprout extract in normal prostate tissue. The investigators hypothesize that consumption of high-sulforaphane broccoli sprout extract every other day will inhibit growth of prostate cancer cells.

What is the current status of trial NCT00946309?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-07. Estimated completion is 2015-05.

What conditions does trial NCT00946309 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00946309?

The interventions under investigation include: High Sulforaphane Extract (Broccoli Sprout Extract) (DRUG), Microcrystalline Cellulose NF (placebo) (DRUG).

Who is sponsoring clinical trial NCT00946309?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00946309 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.